Coronavirus Update: Regeneron Gets Warp Speed Funding, Conflict Slowing Moderna's Progress
Plus: GSK agrees new vaccine collaboration
Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.
You may also be interested in...
Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Coronavirus Update: Hardest Hit US States Will Test Moderna’s Vaccine
A round-up of developments in the COVID-19 vaccine field from Moderna, Fosun, Merck & Co and Medicago and more.
Coronavirus Update: New Clinical Trials Network Could Help Pick Vaccine, Antibody Winners Faster
Plus: the World Health Organization has commissioned an independent panel to look at pandemic responses, while the emergence of an unknown pneumonia in Kazakstan is causing concern.